tirzepatide efficacy Lilly Decides to Advance for Obesity CARDIOVASCULAR EFFICACY OF TIRZEPATIDE IN

10.1016/S0140-6736(05)67698-2 [EL 4

Body composition changes may not be accurately reflected by scale weight alone

6 ADVERSE REACTIONS The following serious adverse reactions are described below or elsewhere in the prescribing information: Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)] Pancreatitis [see Warnings and Precautions (5.2)] Diabetic Retinopathy Complications [see Warnings and Precautions (5.3)] Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.5)] Acute Kidney Injury [see Warnings and Precautions (5.6)] Hypersensitivity [see Warnings and Precautions (5.7)] 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice

high blood sugar in patients

Weight loss was the main reason cited by those taking or considering GLP1s (58%), ahead of diabetes (42%) and heart health (22%)

Question #12 Medically supervised cardiac rehabilitation programs after ASCVD events and for patient with heart failure carries a Class I recommendation